BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the 26th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.
Help employers find you! Check out all the jobs and post your resume.
